Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Sexual Desire Disorder Drug

Flibanserin (Addyi) approved to treat premenopausal women

Indications: Flibanserin (Addyi) is approved for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty.

Dosing: Recommended dosage is 100 mg taken once daily at bedtime. Discontinue treatment after 8 weeks if no improvement.

Pharmacokinetics: Flibanserin showed dose-proportional pharmacokinetics for Cmax after single oral doses of 100 mg to 250 mg (the recommended and 2.5 times the recommended dosage, respectively) in healthy female subjects. Steady state was achieved after 3 days of dosing. The extent of exposure with once-daily dosing of 100 mg of flibanserin was increased 1.4-fold as compared to a single dose.

Effectiveness: In clinical trials, treatment with flibanserin increased the number of satisfying sexual events by 0.5 to 1 additional event per month over placebo, increased the sexual desire score by 0.3 to 0.4 over placebo, and decreased the distress score related to sexual desire by 0.3 to 0.4 over placebo.

Side Effects/Risks: The most common adverse reactions are dizziness, somnolence (sleepiness), nausea, fatigue, insomnia and dry mouth.

More Information: Addyi is not indicated for HSDD due to a co-existing medical or psychiatric condition, problems within a relationship, or the effects of a medication or other drug substance.

Source: Highlights of Prescribing Information: Addyi. U.S. Food & Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526Orig1s000lbl.pdf. Revised August 2015. Accessed August 19, 2015.

This Week's Must Reads

Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al

Diabetes & Long-Term Kidney Disease, Diabetes Care; ePub 2018 Jun 1; Warren, et al

Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al

Efficacy of Brief Behavioral Treatment for Insomnia, Sleep Medicine; ePub 2018 Jun 2; McCrae, et al

Opioid-Related Adverse Events in Surgical Patients, JAMA Surg; ePub 2018 May 23; Shafi, et al

Must Reads in Women's Health

Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al

ACP Position on Women’s Health Challenges, Ann Intern Med; ePub 2018 May 29; Daniel, et al

Aspirin Benefit in Adverse Pregnancy Outcomes, Hypertension; ePub 2018 May 25; Hauspurg, et al

Improving CV Health in Women Through Provider Collaboration, Circulation; ePub 2018 May 10; Brown, et al

Risk of T2D Among Lesbian and Bisexual Women, Diabetes Care; ePub 2018 May 2; Corliss, et al